risperidone has been researched along with Cataract in 4 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Cataract: Partial or complete opacity on or in the lens or capsule of one or both eyes, impairing vision or causing blindness. The many kinds of cataract are classified by their morphology (size, shape, location) or etiology (cause and time of occurrence). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 6.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| "Patients with schizophrenia or schizoaffective disorder participated in the 2-year, randomized, multicentre, open-label, ophthalmologist-masked, flexible-dose, parallel-group study." | 2.80 | Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial. ( Baldycheva, I; Earley, W; Flach, AJ; Laties, AM; Pathak, S; Rak, I, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balamurugan, R | 1 |
| Gupta, PC | 1 |
| Kashyap, H | 1 |
| Ram, J | 1 |
| Laties, AM | 1 |
| Flach, AJ | 1 |
| Baldycheva, I | 1 |
| Rak, I | 1 |
| Earley, W | 1 |
| Pathak, S | 1 |
| Patel, E | 1 |
| Gallego, JA | 1 |
| Valibhai, F | 1 |
| Phan, NB | 1 |
| Still, DJ | 1 |
| True, J | 1 |
1 trial available for risperidone and Cataract
| Article | Year |
|---|---|
Cataractogenic potential of quetiapine versus risperidone in the long-term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open-label, ophthalmologist-masked, flexible-dose, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cataract; Dibenzothiazepines; Female; Humans; Male; M | 2015 |
3 other studies available for risperidone and Cataract
| Article | Year |
|---|---|
Risperidone-induced cataract in a young female.
Topics: Antipsychotic Agents; Cataract; Female; Humans; Lens, Crystalline; Psychotic Disorders; Risperidone; | 2020 |
Bilateral cataracts in a young patient with bipolar disorder on treatment with risperidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Cataract; Humans; Male; Risperidone | 2016 |
Cataracts and quetiapine.
Topics: Adult; Antipsychotic Agents; Cataract; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; | 2001 |